Introduction {#s1}
============

Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 in Saudi Arabia \[[@C1]\] and led to recurring human infections with more than 2500 laboratory-confirmed cases and high case fatality rates of about 35% \[[@C2]\]. In *ex vivo* infection of human lung tissue, MERS-CoV targets bronchial and alveolar epithelial cells (AEC) and leads to a detachment and apoptosis of AEC \[[@C3]\]. Recent reports analysing autopsy material of deceased MERS-CoV-infected patients showed MERS-CoV antigen in AEC and epithelial multinucleated syncytial cell conglomerates *in vivo* \[[@C4], [@C5]\]. Accordingly, severe human infection presents as pneumonia with progression to acute respiratory distress syndrome \[[@C4], [@C5]\].

To date, no vaccine or specific treatment for MERS-CoV - or the recently ongoing pandemic caused by the novel severe acute respiratory syndrome CoV 2 (SARS-CoV-2) - is approved and therapy relies on supportive measures only \[[@C2], [@C6]\]. While *in vitro* studies and experiments in non-human primates demonstrated benefits of a combination of type-I-interferon and antiviral compounds including ribavirin against MERS-CoV \[[@C7]--[@C9]\], results from retrospective patient cohorts applying similar treatment regimens remain controversial \[[@C10]--[@C12]\]. Cyclosporin A (CsA) has been found to inhibit several human-pathogenic CoV in cell lines originating from kidney or liver epithelia \[[@C13]--[@C16]\]. However, the molecular mechanisms by which CsA affects CoV, including MERS-CoV, particularly in its primary target cells, the pulmonary epithelium, remain elusive. Moreover, preclinical studies addressing the effect of CsA or related compounds on MERS-CoV replication *in vivo* have been lacking to date.

CsA is known to block the peptidyl-prolyl cis-trans isomerase (PPI) activity of cyclophilins that is involved in diverse cellular processes (*e.g.* protein folding, \[[@C17]\]). Additionally, CsA forms together with cyclophilin A (CypA) and calcineurin (CnA) a ternary complex which blocks the CnA-dependent activation of NFAT (nuclear factor of activated T-cells), a process which accounts for the immunosuppressive effect of CsA \[[@C18]\]. In addition, CsA has also been shown to inhibit the MAP kinases JNK (c-Jun N-terminal kinase) and p38 \[[@C19], [@C20]\].

Here, we aimed to elucidate the distinct signalling pathways by which CsA affects MERS-CoV in clinically relevant models such as primary human AEC and a murine MERS-CoV infection model \[[@C21], [@C22]\]. We demonstrate that CsA blocks MERS-CoV infectious particle egress, which is dependent on JNK. Moreover, we for the first time provide evidence that CsA triggered the activation of an antiviral defense state in lung epithelial cells. We show that CsA is a potent inducer of Interferon regulatory factor 1 (IRF1), type-III-IFN (IFNλ) and multiple interferon-stimulated genes (ISGs). Additionally, we demonstrate that oral application of CsA induced a robust IFNλ response *in vivo* and, importantly, significantly reduced MERS-CoV replication and improved disease progression in infected mice.

Materials and Methods {#s2}
=====================

MERS-CoV infection {#s2a}
------------------

Experiments with MERS-CoV were performed under biosafety level 4 conditions at the Institute of Virology, Philipps-University of Marburg, Germany. Human alveolar epithelial cells (hAEC) were isolated and cultured as previously described \[[@C23]\]. Human lung tissue was obtained from patients who underwent lobectomy after informed written consent (Departments of Pathology and Surgery, University of Giessen, approved by the University of Giessen Ethics Committee; Az.58/15). Calu-3 or hAEC were infected at a multiplicity of infection (MOI) of 0.1 diluted in DMEM/F12 without FCS at 37°C for 1 h. Cells were washed with DMEM/F12 with 10% FCS and supplemented with stimulatory/inhibitory reagents as indicated. 24 h after infection (pi) cells were processed for quantitative PCR (Maxima-SYBR/ROX qPCR-Mastermix, Thermo Fisher) and supernatant was harvested for virus titration as described previously \[[@C24]\].

*In vivo* transduction and infection {#s2b}
------------------------------------

All animal experiments were performed in accordance with the German animal protection laws and were authorised by the regional authorities (G73/2017). C57BL/6 mice were purchased from Charles River Laboratories and housed under pathogen-free conditions. Mice were intratracheally inoculated with Adenovirus-hDPP4-mCherry (cloned at ViraQuest Inc.) as described \[[@C21], [@C25]\]. 5 days post transduction, mice were infected intranasally with 1.5×10^5^ TCID~50~/mL MERS-CoV (EMC/2012). 50 mg·kg^−1^·day^−1^ CsA diluted in DMSO or DMSO alone were mixed with a nut/chocolate-creme, and offered to the mice for voluntary uptake. Uptake was controlled daily. CsA feeding started 2 days before MERS-CoV challenge. Mice were sacrificed 4 or 7 days post MERS-CoV infection.

RNA-seq analysis {#s2c}
----------------

RNA integrity was assessed on an Experion StdSens RNA Chip (Bio-Rad). RNA-seq libraries were prepared using the TruSeq Stranded mRNA Library Prep kit (Illumina). Libraries were quantified on a Bioanalyzer (Agilent Technologies) and sequenced on an Illumina HiSeq 1500 platform, rapid-run mode, single-read 50 bp (HiSeq SR Rapid Cluster Kit v2, HiSeq Rapid SBS Kit v2, 50 cycles) according to the manufacturer\'s instructions. Quality control of RNA-seq reads was performed using the FastQC command line tool version 0.11.7. Reads were aligned using STAR version 2.7.0d to an index based on hg38 human genome version. Gene-specific read counts based on hg38 UCSC gene annotations were extracted using FeatureCounts from the Subread package version 1.6.3. Resulting read counts were imported into R. Detection of differentially expressed genes was done using DESeq2 version 1.22.1. Subsequent data analysis and visualisation was done with custom R scripts. GO overrepresentation analysis was performed using the enrichGO function of the clusterProfiler package version 3.10.1. Sequencing data are available at Array Express, accession number E-MTAB-8222.

Statistics {#s2d}
----------

All data are given as mean±[sem]{.smallcaps}. Statistical significance was analysed by unpaired two-tailed Student\'s t-test or by 1-way ANOVA and post-hoc multi-comparison tests as indicated in the respective figures. A p value of less than 0.05 was considered significant. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.005.

*Further experimental details can be found in the* [Online Supplement](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials).

Results {#s3}
=======

Cyclosporin A (CsA) inhibits MERS-CoV replication and release in lung epithelia {#s3a}
-------------------------------------------------------------------------------

To address the previously proposed antiviral activity of CsA in clinically relevant cells, we infected the human bronchial epithelial cell line Calu-3 and primary human alveolar epithelial cells (hAEC) with MERS-CoV and analysed intracellular viral RNA and infectious particle release in presence of DMSO or CsA ([fig. 1](#F1){ref-type="fig"}). In both Calu-3 and hAEC, CsA treatment led to a \>95% decrease of viral RNA ([fig. 1a](#F1){ref-type="fig"}) and a reduction of viral titers in the supernatant by 2.6--2.8 log~10~, respectively ([fig. 1b](#F1){ref-type="fig"}). Interestingly, and in accordance with reports from autopsy material of MERS-CoV patients \[[@C4]\], MERS-CoV-infected Calu-3 and primary hAEC both showed apoptotic cell loss and formation of multinucleated cell foci ([fig. 1c](#F1){ref-type="fig"}). Addition of CsA reduced cell foci formation and significantly reduced apoptosis induction ([fig. 1c](#F1){ref-type="fig"} and d). In line, both CFTR (cystic fibrosis transmembrane conductance regulator; [fig. 1e](#F1){ref-type="fig"}) and ENaCβ (epithelial sodium channel beta; [Supplement Fig.E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials)) protein expression was improved after addition of CsA to MERS-CoV-infected Calu-3. Moreover, epithelial structural integrity and ability for vectorial water transport were reduced in MERS-CoV-infected control cells and significantly improved to normal levels in MERS-CoV-infected, CsA-treated cells ([fig. 1f](#F1){ref-type="fig"} and g).

![Cyclosporin A (CsA) inhibits MERS-CoV replication and release in human airway epithelial cells and primary human alveolar epithelial cells (hAEC). Calu-3 and hAEC were infected with MERS-CoV using an MOI of 0.1, stimulated with DMSO or 10 µM Cyclosporin A (CsA), and analysed at 24 h pi. In (a), total RNA was isolated from cell lysates and viral RNA content was analysed by qPCR. After normalisation to actin, changes in RNA content in CsA-treated cells were normalised to RNA present in DMSO-treated control groups (set at 100%). In (b), virus titers were determined by TCID~50~ method from cell-free culture supernatant and shown as logTCID~50~/mL. In addition, (c) MERS-CoV-induced CPE and foci formation (marked by arrows) was documented in live cells by phase contrast microscopy at a magnification of 100x. d) Apoptosis induction was quantified by Caspase 3/7 Glo® Assay in Calu-3. In (e), cell lysates were analysed by western blot for expression of CFTR (168 kDa) and vinculin (120 kDa). Left panel shows representative western blots of n=3--4 experiments. Right panel shows relative quantitation with mock samples set to 100%. f, g) Calu-3 were grown on transwell filters and treated as above. Epithelial integrity was quantified by transepithelial resistance measurements (f) and vectorial water transport evaluated by FITC-Dextran quantification 48 h pi (g). Bar graphs in (a, b, d--g) represent means±[sem]{.smallcaps} of n=3--6 experiments. Statistical significance was analysed by unpaired 2-tailed Student\'s *t*-test (a, b) and one-way-ANOVA and Bonferroni\'s multiple comparisons test(d--g), where all groups were compared to each other. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.005. Shown micrographs (c) are representative of n\>5 experiments.](ERJ-01826-2019.01){#F1}

Csa treatment affects MERS-CoV infection *via* CypA- and MAPK-signalling pathways {#s3b}
---------------------------------------------------------------------------------

CsA is known to act *via* multiple signalling pathways including cyclophilin PPIase activity, the CnA-NFAT axis as well as MAP kinase signalling \[[@C17]--[@C20]\]. Using specific inhibitors, we aimed to interfere with CsA-affected pathways to identify relevant molecular signalling events involved in the CsA-mediated reduction of MERS-CoV infection. Inhibition of CnA by its specific inhibitor calcineurin inhibitory peptide (CIP), as well as inhibition of the downstream transcription factor NFAT resulted in minor, statistically non-significant changes in MERS-CoV viral titers in both Calu-3 and hAEC ([fig. 2a](#F2){ref-type="fig"} and b). The non-immunosuppressive derivate of CsA, Alisporivir (ALV), that binds the PPIase but does not induce ternary complex formation of CypA with CnA, reduced viral titers to a similar extent as CsA, suggesting that the CypA-PPIase activity elicits the restrictive effect on MERS-CoV replication rather than ternary complex-mediated signalling events. Moreover, ALV reduced cell foci formation and loss of epithelial integrity to a similar extent as CsA ([Supplement Fig. E2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials)). Applying specific MAPK inhibitors against JNK and p38, we revealed that inhibition of the MAP kinase JNK, but not of p38 reduced MERS-CoV titers in both Calu-3 and hAEC ([fig. 2a](#F2){ref-type="fig"} and b). However, neither inhibition of CnA-dependent signalling nor inhibition of JNK or p38 could reproduce the CsA-induced attenuation of MERS-CoV RNA accumulation. In addition, JNK inhibition had no positive effect on cell foci formation or epithelial integrity after MERS-CoV infection ([Supplement Fig. E3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials)). These data suggest a role for JNK activity late in MERS-CoV replication, where adverse effects on epithelial integrity are still displayed while viral release is blocked. Of note, application of ALV resulted in a strong reduction of MERS-CoV RNA levels similar to CsA ([fig. 2c](#F2){ref-type="fig"} and d). Together, these results indicate that a CsA-induced, CypA-dependent effect has major impact on early replication steps of MERS-CoV, strongly reducing viral RNA accumulation, even prior to virus release, independently of CnA, NFAT or JNK.

![Effect of CsA, ALV, and inhibition of CsA-dependent CnA/NFAT and MAPK pathways on MERS-CoV infection. Calu-3 (a, c) and hAEC (b, d) were infected with MERS-CoV using an MOI of 0.1. 1 h after viral adsorption, cells were stimulated with either CsA (10 µM), its non-immunosuppressive derivate Alisporivir (ALV, 10 µM), Calcineurin (CnA) inhibitor (CIP, 20 µM), NFAT inhibitor (50 µM), JNK inhibitor (SP600125, 10 µM), p38 MAPK inhibitor (SB 203 580, 10 µM) or DMSO as solvent control. In (a, b), virus titers were determined by TCID~50~ method from cell-free culture supernatant and shown as logTCID~50~/mL. In (c, d), total RNA was isolated from cell lysates at 24 h pi and viral RNA content was analysed by qPCR. After normalisation to actin, changes in RNA content in CsA-treated cells were normalised to RNA present in DMSO-treated control groups (set at 100%). Bar graphs represent means±[sem]{.smallcaps} of n=6--8 experiments for DMSO and CsA groups and 3--5 experiments for ALV, CnA, NFAT, JNK and p38 inhibitors. Statistical significance was analysed by one-way-ANOVA and Bonferroni\'s multiple comparisons test, where all groups were compared to each other. Statistical significances in comparison to DMSO control are indicated in the graph. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.005; ns=not significant.](ERJ-01826-2019.02){#F2}

Csa treatment evokes an interferon-driven antiviral state in lung epithelial cells {#s3c}
----------------------------------------------------------------------------------

Our data suggest that, as opposed to its well-known CnA/NFAT-mediated immune-suppressive effects on immune cells, CsA might evoke an antiviral state in human lung epithelial cells. To identify the underlying mechanism, we performed RNA sequencing analysis on CsA- *versus* DMSO-treated Calu-3 cells. Of note, analysis of enriched gene sets based on GO terms revealed that the most significantly upregulated biological processes after CsA treatment included responses to viruses and, importantly, antiviral interferon responses ([fig. 3a](#F3){ref-type="fig"}). In line with these results, both the type-I-IFN gene *IFNB* and type-III-IFN genes *IFNL1* and *IFNL2* were among the top-50, or, in case of *IFNL1*, top-10 most upregulated genes in CsA-treated cells ([fig. 3b](#F3){ref-type="fig"} and c). Many of the upregulated genes were known interferon-stimulated genes (ISGs), including *MX*1, *MX2*, *OAS1*, *OAS2*, *IFIT1*, *IFIT2*, *IFIT3*, *LAMP3*, *BST2/tetherin*, *RSAD2/viperin* or *CXCL10* ([fig. 3b](#F3){ref-type="fig"}).

![CsA treatment induces an antiviral response state in Calu-3 lung epithelial cells. Calu-3 cells were stimulated with 10 µM CsA or treated with DMSO as vehicle control. At 24 h post stimulation, total RNA was isolated and subjected to transcriptome analysis (see methods section). In (a), an over-representation analysis of GO biological processes was calculated using upregulated genes with a Log2FoldChange \>1. The 10 most significant biological processes are plotted in order of gene ratio. The size of the dots represents the number of genes in the upregulated gene list associated with the GO term; the colors of the dots represent p-adjusted values. Individual genes are shown as heat map in (b) listing the top 50 regulated genes (up and down) and as volcano plot (c). Data represent two independent experiments.](ERJ-01826-2019.03){#F3}

To validate our results, we analysed mRNA expression of both type-I and type-III-IFN by qRT-PCR in CsA-stimulated or DMSO-treated Calu-3 cells. We found a moderate upregulation of *IFNB* (up to 57 fold change over mock) and no significant induction of *IFNA* ([fig. 4a](#F4){ref-type="fig"}, upper panels). However, we revealed a strong induction of *IFNL1* and *IFNL2/3* mRNAs (between 150 and 387 fold change over unstimulated mock control, respectively; [fig. 4a](#F4){ref-type="fig"}, lower panels). Quantification of IFNλ1 and IFNλ3 protein release from cell culture supernatants by ELISA demonstrated a robust induction upon CsA addition as early as 12 h after CsA treatment, reaching peak values of 4222±890 ng protein mL^−1^ at 48 to 56 h after CsA application ([fig. 4b](#F4){ref-type="fig"}). Similarly, treatment with ALV induced robust IFNλ release within reaching a similar maximum release of IFNλ after 72 h ([Supplement Fig.E4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials)). We next validated the CsA-induced upregulation of ISGs and confirmed an increased expression of selected ISGs including *MxA*, *PKR*, *OAS1*, *IFIT1*, *IFIT2*, *IFIT3*, *Bst2/tetherin*, *RSAD2/viperin* and *XAF1* upon 18 h treatment with CsA compared to vehicle-treated control cells ([fig. 4c](#F4){ref-type="fig"}). These data indicate that CsA treatment mounts a distinct interferon-driven antiviral response in lung epithelial cells.

![CsA induces IFNλ mRNA and release. Calu-3 cells were stimulated with 10 µM CsA, followed by (a) total RNA isolation at 15, 18, 21, and 26 h after treatment. After cDNA synthesis, qPCR-analysis was performed for *IFNA*, *IFNB*, *IFNL1* and *IFNL2/3*. Fold change over DMSO-stimulated control was performed (2^−ΔΔCt^) to visualise IFN-induction upon CsA stimulation. For quantification of released IFNλ (b), supernatants of CsA-stimulated Calu-3 cells were collected from 6 to 56 h after CsA treatment and IFNλ1/3 was determined by ELISA. c) Expression of selected ISGs upon CsA treatment was analysed at 18 h post CsA-treatment by qPCR-analysis and fold change over DMSO-stimulated control (2^−ΔΔCt^). Bar graphs represent means±[sem]{.smallcaps} of n=3--5 experiments in (a, b) and of n=3 experiments in (c). Grey, dotted line in (b) represents the minimal detection limit of the ELISA as given by the manufacturer.](ERJ-01826-2019.04){#F4}

IFNλ-induction is mediated by IRF1 upon CsA treatment in lung epithelial cells {#s3d}
------------------------------------------------------------------------------

To better understand the transcriptional programs leading to IFNλ induction in CsA-treated cells, we analysed the regulation of interferon regulatory factors (IRFs). Our data reveal significant upregulation of *IRF1* mRNA levels upon CsA treatment, but not of *IRF3*, *IRF7* or *IRF9* ([fig. 5a](#F5){ref-type="fig"}). IRF1 is known to be a specific activator of *IFNL* gene expression \[[@C26]\]. Accordingly, we identified a significantly increased number of IRF1-expressing cells in CsA-stimulated Calu-3 cells by immunofluorescence ([fig. 5b](#F5){ref-type="fig"}). In line, *IRF1* siRNA knockdown significantly reduced *IFNL* mRNA levels in CsA treated Calu-3 cells ([fig. 5c](#F5){ref-type="fig"}). Accordingly, *IRF1* knockdown inhibited IFNλ release by more than 75% as compared to control ([fig. 5d](#F5){ref-type="fig"}).

![IRF1 mediates the CsA-induced expression of IFNλ. a) Calu-3 cell lysates were collected 4 h post treatment with 10 µM CsA or DMSO control. Total RNA was isolated, and qPCRs for *IRF1*, *IRF3*, *IRF7*, and *IRF9* was performed. Data are presented as fold change over DMSO (2^−ΔΔct^). b) Expression of IRF1 in CsA or DMSO stimulated Calu-3 cells was analysed by indirect immunofluorescence on fixed and permeabilized cells (left panel). Nuclei were counterstained with DAPI. For quantification of IRF1 expression (right panel), the ratio of IRF1^positive^ to DAPI^positive^ cells were counted in at least 10 randomly chosen microscopic fields of 3 independent experiments. In (c, d), *IRF1* was silenced by siRNA-transfection experiments using oligofectamine. Scrambled siRNA transfection was used as control. At 4 h post transfection, Calu-3 cells were treated with 10 µM CsA. c) Supernatants were collected 18 h after CsA treatment. *IFNL* mRNA was analysed *via* qPCR. Data are shown as relative fold induction in comparison to non-siRNA treated cells (set to 100%). In (d) supernatants of siRNA-transfected and CsA stimulated cells were analysed by ELISA. Data are shown as relative amount of IFNλ in comparison to non-siRNA treated cells (set to 100%). Bar graphs represent means±[sem]{.smallcaps} of n=3--4 experiments for (a), n=3 experiments for (b, c), and n=4 experiments for (d). Statistical significance was calculated using unpaired 2-tailed Student\'s *t*-test for (b) and one-way ANOVA and Bonferroni\'s multiple comparisons test comparing all groups to each other (c, d). \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.005; ns not significant.](ERJ-01826-2019.05){#F5}

Inhibition of the IRF1-IFNλ signalling axis counteracts the MERS-CoV restrictive effect of CsA {#s3e}
----------------------------------------------------------------------------------------------

To understand the extent to which the inhibition of MERS-CoV propagation in CsA treated cells was mediated by IRF1-mediated production of IFNλ, we performed knockdown of *IRF1* or neutralised cell-free IFNλ, respectively. Our data demonstrated that silencing of *IRF1* but not treatment by control siRNA lead to a significant increase in MERS-CoV released viral particles in CsA-treated cells ([fig. 6a](#F6){ref-type="fig"} and b). Moreover, neutralising antibodies directed against IFNλ1, IFNλ2 and IFNλ3 or against the less induced IFNβ were applied ([fig. 6b](#F6){ref-type="fig"}). Neutralisation of IFNβ had no significant impact on MERS-CoV replication after CsA treatment, whereas application of anti-IFNλ1/2/3 treatment significantly increased MERS-CoV viral titers by 1.05 log~10~ level ([fig. 6b](#F6){ref-type="fig"}). These data indicate that the antiviral effects of CsA were at least partially mediated by an IRF1-IFNλ signalling axis, and independent of type-I-IFN.

![Inhibition of the IRF1-IFNλ signalling axis partially prevents the CsA-induced effects on MERS-CoV replication. a) *IRF1* was silenced by siRNA-transfection experiments using oligofectamine. Scrambled siRNA transfection was used as control. At 20 h post transfection, Calu-3 cells were infected with MERS-CoV at MOI 0.1 and after 1 h of viral adsorption cells were treated with 10 µM CsA or DMSO solvent control. 24 h pi, viral release was determined by TCID~50~. In (b), Calu-3 cells were infected with MERS-CoV at MOI 0.1 and stimulated with CsA or DMSO control as described before. In parallel, neutralising antibodies targeting IFNβ or IFNλ1/2/3 were added simultaneously with CsA. 24 h pi viral release was determined by TCID~50~. Bar graphs represent means±[sem]{.smallcaps} of n=4 experiments in (a), and n=6--7 experiments in (b). Statistical significance was calculated using one-way ANOVA and Bonferroni\'s multiple comparisons test, where all groups were compared to each other. Statistical significances in comparison to the oligofectamin-only treated group are indicated in the graph. \*p\<0.05; \*\*p\<0.01; ns not significant.](ERJ-01826-2019.06){#F6}

CsA-treatment upregulates IFNλ and leads to reduced MERS-CoV replication and lung pathology *in vivo* {#s3f}
-----------------------------------------------------------------------------------------------------

To validate the antiviral efficacy of CsA against MERS-CoV *in vivo*, we used our recently established MERS-CoV infection mouse model that is based on the intratracheal delivery of the human DPP4 receptor to lung epithelial cells *via* adenoviral transduction, leading to severe MERS-CoV infection that presents as necrotising interstitial pneumonia \[[@C22]\]. We treated mice daily *via* oral intake of either DMSO or CsA, starting 2 days before mock or MERS-CoV infection. Oral CsA application resulted in CsA serum levels of 202 to 356 ng·mL^−1^ (mean 270 ±17 ng·mL^−1^), a concentration that compares to levels reached in patients under CsA treatment ([Supplement Figure E5](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials), 34, 35). Accordingly, CsA treatment significantly induced release of IFNλ in the bronchoalveolar lavage fluid ([fig. 7a](#F7){ref-type="fig"}). *IFNL* induction was significantly elevated in the CsA treatment group compared to DMSO-treated mice at day 7 post MERS-CoV infection ([fig. 7b](#F7){ref-type="fig"}). Oral application of CsA significantly reduced viral titers (3.45 ±0.15 *versus* 2.1 ±0.36 TCID~50~/mL in the DMSO *versus* CsA group) at day 7 post MERS-CoV infection ([fig. 7c](#F7){ref-type="fig"}). CsA treatment did not alter adenoviral transduction efficiency ([Supplemental Fig. E6](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials)). Of note, expression levels of *IFNL* inversely correlated with MERS-CoV load in lung homogenates at day 7 pi ([fig. 7d](#F7){ref-type="fig"}). A significant reduction in viral titers and a significant correlation between *IFNL* induction and MERS-CoV inhibition could also be demonstrated at day 4 pi ([Supplement Fig. E7](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials)). Expression of the *SCNN1B* gene (ENaCβ) as a marker of epithelial integrity was improved in lung homogenates of MERS-CoV-infected mice treated with CsA ([fig. 7e](#F7){ref-type="fig"}). While extensive edema formation was present in a substantial portion of MERS-CoV-infected mice, it was absent in the CsA-treated group ([Supplement Fig. E8](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01826-2019.figures-only#fig-data-supplementary-materials)). Importantly, the percentage of lung areas showing histopathological alterations due to MERS-CoV infection was significantly decreased by CsA treatment at day 7 post infection ([fig. 7f](#F7){ref-type="fig"}). Collectively, we demonstrate that oral application of CsA induced IFNλ in the lungs of mice and exerted potent antiviral activity *in vivo*.

![CsA-treatment upregulates IFNλ and reduces MERS-CoV replication *in vivo.* a) Mice were fed with CsA (50 mg·kg^−1^·day^−1^) or DMSO as solvent control. After 6 days of daily oral application, levels of IFNλ were analysed by ELISA from the bronchoalveolar lavage fluid. b--f) Mice were intratracheally infected with an adenovirus construct encoding for human DPP4 and mCherry (Ad-hDPP4). Oral application of CsA (50 mg·kg^−1^·day^−1^) or DMSO as solvent control was started at day 3 post transduction, while mice were infected with 1.5×10^5^ TCID~50~/mL MERS-CoV *via* the intranasal route at day 5 post transduction. Mice were euthanized and lungs were isolated 7 days post MERS-CoV infection. Lung homogenate was used to quantify (b) relative *IFNL2/3* mRNA and (c) determine viral load by TCID~50~. In (d) correlation between MERS-CoV titers and *IFNL2/3* mRNA expression levels was calculated using Pearson correlation efficient. In (e) relative amounts of *SCNNB1* (ENaCβ) RNA were determined *via* qPCR from lung homogenates of MERS-CoV-infected and DMSO- *versus* CsA-treated mice. In (f), lungs were fixed and processed for histological analysis. Lung areas characterised by interstitial inflammation typical for MERS-CoV-induced pneumonia \[[@C22]\] were quantified after whole lung processing. Statistical significance was calculated using unpaired two-way student\'s t-test (a, b, c, d, g) with \*p\<0.05.](ERJ-01826-2019.07){#F7}

![CsA and ALV restrict MERS-CoV *via* induction of interferon lambda. Addition of cyclophilin inhibitors, including CsA or its non-immunosuppressive derivate ALV are known modulators of Cyclophilin A (CypA) and induce activation of the interferon regulatory transcription factor IRF1. Subsequently, transcription of type III interferon genes (*IFNL*) is upregulated and IFNλ is released both *in vitro* and *in vivo*. CsA further induces the expression of interferon stimulated genes (ISGs), likely by auto- and paracrine signalling *via* IFNλ. CsA-induced ISGs include molecules with a known antiviral effect, *e.g.* OAS1 or IFIT1, which in turn convey the restrictive effect of CsA on MERS-CoV replication.](ERJ-01826-2019.08){#F8}

Discussion {#s4}
==========

With the appearance of SARS-CoV in 2002, MERS-CoV in 2012 and recently SARS-CoV-2, three species of the family *Coronaviridae* have revealed the ability to be efficiently transmitted from human-to-human and to provoke serious disease with high mortality rates. Both SARS-CoV and MERS-CoV are listed on the WHO blueprint list of priority diseases, and the zoonotic CoV reservoir strains are generally considered and have now been proven to be a source for emerging pandemic viruses.

As no specific treatment is approved for MERS-CoV or SARS-CoV(-2), current treatment strategies are supportive \[[@C29], [@C30]\]. Treatments including recombinant type-I-IFN and antivirals (*e.g.* Lopinavir/Ritonavir) have been applied off-label to treat MERS-CoV and yielded only moderate efficacy with controversial results in retrospective studies, and data from prospective studies or randomised controlled trials are lacking \[[@C29], [@C31]--[@C33]\]. Due to its receptor specificity to the human DPP4, only few animal models to study MERS-CoV pathogenesis and MERS-CoV-directed antiviral compounds have been accessible to date. For this study, MERS-CoV infection in the mouse was facilitated *via* intratracheal delivery of a human DPP4-encoding adenovirus, that might cause low-level inflammation itself and inhomogeneous receptor distribution within the lung, present for a limited time frame. However, even if this model might not fully recapitulate the native cellular distribution or density of the receptor as seen in the human lung, high transduction efficiencies (≥ 95%, data not shown) allow efficient viral spread in the upper and lower respiratory airways with quick progression to severe lung injury \[[@C22]\] and with moderate changes in morbidity \[[@C34]\]. Thus, model-specific neurotropism as seen in some of the transgenic hDPP4 mice \[[@C35]\] or the necessity to adapt virus isolates *via* multiple passages, which might potentially affect its susceptibility to interventional strategies, are circumvented. While prior exposure to adenovirus evokes moderate histological changes including perivascular and bronchiolar lymphocytic infiltration (data not shown), MERS-CoV infection led to a clearly distinguishable granulocytic, necrotising interstitial pneumonia with alveolar edema formation as described previously \[[@C22]\].

CsA has been implicated as inhibitor of a broad spectrum of virus families, including diverse CoV \[[@C14], [@C36]--[@C41]\]. However, studies on efficacy of CsA against CoV infection relied on results in liver and kidney cell lines \[[@C14]--[@C16]\], while results from primary lung epithelial target cells were lacking. Recently, CsA was demonstrated to restrict MERS-CoV *ex vivo* \[[@C13]\]. Still, insights on mechanistic details and on the question if CsA application would affect MERS-CoV infection *in vivo* remained elusive.

We now demonstrate that CsA application blocks MERS-CoV both at mRNA level and the amount of infectious viral particles released and significantly improves epithelial barrier integrity after MERS-CoV infection. Using different inhibitors known to block CsA-targeted pathways, we reveal that the CsA-induced blockade of MERS-CoV RNA synthesis can neither be reproduced by inhibition of known CsA-targeted MAP kinases nor by blockade of NFAT activation. Of note, ALV, which blocks CypA PPIase activity efficiently, but affects NFAT-dependent pathways only at very high concentrations \[[@C42]\], diminished MERS-CoV RNA accumulation as efficiently as CsA, suggesting that CypA plays a pivotal role in these processes. In fact, we revealed a previously unknown activation of genes involved in innate immune responses and in limitation of virus replication upon administration of CsA to lung epithelial cells. Moreover, we demonstrate that inhibition of CypA *via* CsA or ALV, which both potently block the CypA PPIase activity at the used concentrations \[[@C42]\], results in a pronounced upregulation of type-III-IFN on both mRNA and protein level, which was mediated *via* IRF1 and was accompanied by expression of antiviral ISGs. Among those, especially IFIT1 (Interferon-induced protein with tetratricopeptide repeats 1), has been reported to influence the pathogenesis of MERS-CoV, highlighting the relevance of our findings \[[@C43]\].

Of note, type-III-IFNs have recently emerged as key antiviral players in the innate immune response to viral infections at mucosal and epithelial surfaces \[[@C44]--[@C47]\]. They efficiently restrict different respiratory viruses, and act *e.g.* by limiting spread from the upper to the lower airways \[[@C44], [@C46]--[@C48]\]. As opposed to type-I-IFN, type-III-IFN do not trigger detrimental immune responses that contribute to immunopathology in influenza infection \[[@C23], [@C25], [@C44], [@C49]\]. This might prove to be pivotal in the context of CsA-dependent stimulation of IFNλ during CoV, as severe human CoV infections, like MERS-CoV and-- while data are still limited -- also SARS-CoV-2, are characterised by an immunopathology with a strong cytokine induction \[[@C5], [@C50], [@C51]\].

In addition to defining a novel pro-inflammatory, antiviral expression profile induced by CsA on lung epithelial cells, this study also demonstrated for the first time that oral application of CsA reduces viral load in an *in vivo* MERS-CoV infection model. CsA is a licensed drug in clinical use since the 1980s. While prolonged treatment (over weeks and months) with CsA can induce side effects (*e.g.* nephrotoxicity; 48), we here applied a short-interval oral intake of CsA during acute infection. Our results demonstrate that *in vivo*, oral application over 6 days results in drug serum levels efficiently inhibiting lung viral infection and pneumonia progression, highlighting CsA as a promising drug to be re-purposed for treatment of MERS-CoV.

Notably, our *in vitro* studies also revealed that neutralisation of type-III-IFNs did not completely reverse the MERS-CoV-restrictive effect of CsA. We therefore suggest that CsA affects MERS-CoV at multiple steps during viral replication. In fact, we show that CsA acts on MERS-CoV propagation *via* inhibition of JNK, which is another downstream target of CsA \[[@C19], [@C53]\]. JNK inhibition has no impact on MERS-CoV RNA accumulation but strongly reduces the amount of released infectious virions. While the exact underlying molecular mechanisms remain to be defined, this finding demonstrated that CsA likely exerts additive effects to restrict MERS-CoV replication. While application of recombinant IFNs are approved to treat virus infections and malignancies, severe side effects have been related to systemic IFN application \[[@C54]\]. CsA repurposing for treatment of (MERS-) CoV infection might therefore come with several advantages over IFN treatment, such as additional antiviral effects beyond those mediated by IFNλ alone, a favorable side effect profile upon short-term use, a beneficial effect regarding an overshooting immune response characterising CoV disease \[[@C55], [@C56]\] and proven oral availability (64, 65). CsA therefore represents a promising therapeutic option to combat human CoV infections, potentially extending over MERS-CoV to the current pandemic SARS-CoV-2 strain and future CoV threats.
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